ESMO 2023 | Managing toxicities in advanced urothelial cancers: insights on EV and erdafitinib

Rob Jones, MD, PhD, The University of Glasgow, Glasgow, UK, discusses advancements in managing advanced urothelial cancers, highlighting pivotal Phase III data for new targeted therapies including enfortumab vedotin (EV) plus pembrolizumab in EV-302 (NCT04223856) and erdafitinib in THOR (NCT03390504). EV has gained extended indications, demonstrating transformative outcomes in first-line treatment when combined with pembrolizumab. Additionally, erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor, exhibits efficacy in patients with prior platinum-based chemotherapy and immunotherapy. Both therapies present new challenges in terms of toxicities, emphasizing the importance of proactive management. Prof. Jones delves into specific toxicities such as neuropathy and skin toxicity associated with EV, as well as hypophosphatemia and retinitis with erdafitinib. Patient education, close monitoring, and collaboration with specialists are crucial for optimizing treatment outcomes. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.